Credo Technology stock jumps as Broadcom backs copper over optical links in AI data centers

Credo Technology stock jumps as Broadcom backs copper over optical links in AI data centers

March 6, 2026

SAN JOSE, Calif., March 6, 2026, 06:06 PST

Credo Technology Group Holding Ltd shares jumped nearly 12% on Thursday after Broadcom said its AI-chip customers would likely “stay on direct attached copper” inside racks as data rates rise, lending support to the copper-link market at the heart of Credo’s growth story. The shares were last quoted at $114.74, up 11.9% from the previous close, according to LSEG data. The Motley Fool

The move lands in the middle of a live fight over how AI clusters will be wired. Nvidia on Monday agreed to invest $2 billion each in optical suppliers Lumentum and Coherent, while Broadcom Chief Executive Hock Tan said customers would likely stay on direct-attached copper, keeping the debate alive over co-packaged optics, or CPO, a design that moves optical links closer to chips.

Broadcom was speaking about copper links broadly. Credo’s main bet is active electrical cables, or AECs, copper interconnects used to connect servers and switches in AI data centers. On the company’s earnings call this week, Chief Executive Bill Brennan said AECs were “becoming de facto” in inter-rack connections because of “network reliability and power efficiency.” Credo

Credo said on Monday that fiscal third-quarter revenue rose 201.5% from a year earlier to $407 million. It forecast current-quarter revenue of $425 million to $435 million, and Brennan said the company remained confident it could “innovate and grow” as AI infrastructure demand expands. Credo Technology Group

The comments rippled through peers. Lumentum shares were last quoted down 4.5% and Coherent down 7.6%, while Broadcom was up 4.8%, according to LSEG data. That unwound part of the enthusiasm that had lifted the optical names earlier this week after Nvidia’s investment.

The bigger backdrop is still spending. Broadcom said it now sees a line of sight to more than $100 billion in AI chip revenue in 2027, and Big Tech companies including Alphabet, Microsoft, Amazon and Meta are expected to spend at least $630 billion on AI infrastructure this year. D.A. Davidson analyst Gil Luria said that kind of visibility pointed to “significant growth in demand.” Reuters

Credo is not staying on one side of the argument. Brennan told analysts the company expects AEC and integrated-circuit sales to keep growing in fiscal 2027, while ZeroFlap optics begins to ramp; active LED cables and the first OmniConnect gearbox products are slated to layer in during fiscal 2028. That gives Credo exposure to both copper and optical builds as customers shift designs.

But the setup can still turn fast. Credo forecast fourth-quarter GAAP gross margin of 63.9% to 65.9%, down from 68.5% in the latest quarter, and management said fiscal 2027 would bring a different mix between copper and optical as new products ramp. If optics move faster than Credo expects, or if the new mix weighs on margins for longer, the stock could come under pressure again.

Konrad Wysocki

Konrad Wysocki is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Rzeszów, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • Unapproved Weight Loss Drug Linked to Liver Failure in Australia
    June 19, 2026, 8:01 PM EDT. Unapproved weight loss drug retatrutide, marketed illicitly as a fast-acting peptide, has caused acute liver failure in multiple users in Melbourne, according to senior doctors and Victoria's Chief Health Officer. The injectable medication lacks approval from major regulators, including the US FDA and Australia's TGA. One patient, Megan Hancocks, was hospitalized with severe liver toxicity after self-administering the black market drug purchased from unverified sources. She remains on steroids and unable to work months later. Health authorities warn the public against purchasing or using such counterfeit products due to severe risks. The department issued a health alert following six confirmed cases of liver toxicity linked to this product, emphasizing potential dangers of unregulated weight loss treatments.